To further investigate the effects of activation of FBXL2 on the growth of osimertinib-resistant NSCLC, we established PC-9 cells stably expressing EGFRT790M/C797S (PC-9/AZDR), which are resistant to osimertinib (Supplementary Fig. 10c). Here, FBXL2 is linked to non-small cell lung carcinoma.